Weekly Roundup on the Cannabis Sector & Psychedelic Sector | Market Exclusive

Key Takeaways; Cannabis Sector Cresco Labs Reported Q4 Revenue Growth Momentum as Margins Improved Tilray Expanded Beverage Push With $60 Million BrewDog Asset Acquisition Key Takeaways; Psychedelic Sector Helus Pharma Reported Promising Phase 2 Results for Anxiety Treatment GH Research Highlighted Strong 2025 Progress as It Prepares to Advance Its Depression Therapy Program AtaiBeckley is Advancing Psychedelic Therapy Pipeline as Phase 3 Depression Trial Nears Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends. Top Marijuana Companies for the Week #1: Cresco Labs Cresco Labs Inc. ( CSE: CL ) ( OTCQX: CRLBF ) reported a narrower quarterly loss and slightly better-than-expected revenue for the fourth quarter of 2025, while highlighting improved margins and cash generation as the cannabis company positions itself for what it called “industry consolidation”. The Chicago-based cannabis operator posted an adjusted loss of $0.02 per share, matching analyst estimates but slightly wider than the $0.01 loss recorded a year earlier. Revenue for the quarter
Read More